Context-specific role of SOX9 in NF-Y mediated gene regulation in colorectal cancer cells

Zhongcheng Shi1, Chi-I Chiang1, Paul Labhart2, Yanling Zhao3, Jianhua Yang3, Toni-Ann Mistretta1, Susan J. Henning4, Sankar N. Maity5 and Yuko Mori-Akiyama1,∗

1Department of Pathology & Immunology, Baylor College of Medicine, Texas Children’s Hospital, 1102 Bates Street, Suite FC 830.27, Houston, TX 77030-2399, USA, 2Active Motif, 1914 Palomar Oaks Way, Suite 150, Carlsbad, CA 92008, USA, 3Department of Pediatrics, Baylor College of Medicine, Texas Children’s Cancer Center, Houston, TX 77030-2399, USA, 4Department of Medicine, Cell Biology & Physiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7032, USA and 5Department of Genitourinary Medical Oncology—Research, Division of Cancer Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA

Received November 24, 2014; Revised May 15, 2015; Accepted May 19, 2015

ABSTRACT

Roles for SOX9 have been extensively studied in development and particular emphasis has been placed on SOX9 roles in cell lineage determination in a number of discrete tissues. Aberrant expression of SOX9 in many cancers, including colorectal cancer, suggests roles in these diseases as well and recent studies have suggested tissue- and context-specific roles of SOX9. Our genome wide approach by chromatin immunoprecipitation sequencing (ChIP-seq) in human colorectal cancer cells identified a number of physiological targets of SOX9, including ubiquitously expressed cell cycle regulatory genes, such as CCNB1 and CCNB2, CDK1, and TOP2A. These novel high affinity-SOX9 binding peaks precisely overlapped with binding sites for histone-fold NF-Y transcription factor. Furthermore, our data showed that SOX9 is recruited by NF-Y to these promoters of cell cycle regulatory genes and that SOX9 is critical for the full function of NF-Y in activation of the cell cycle genes. Mutagenesis analysis and in vitro binding assays provided additional evidence to show that SOX9 affinity is through NF-Y and that SOX9 DNA binding domain is not necessary for SOX9 affinity to those target genes. Collectively, our results reveal possibly a context-dependent, non-classical regulatory role for SOX9.

INTRODUCTION

SOX proteins, high-mobility group, (HMG)-box transcription factors, play crucial roles in embryonic and adult diverse tissues; these include maintenance of stem cell properties, lineage specification and terminal differentiation in a cell-type and tissue-specific manner. In the intestinal epithelium, SOX9 is expressed in the stem/progenitor cells, as well as in the nuclei of terminally differentiated Paneth cells of the small intestinal crypts and tuft cells in the villi and it plays a crucial role in Paneth cell differentiation (1,2). Aberrant expression of SOX9 in some human cancers, including colorectal cancer and in Apc(min/+)- mouse intestinal adenomas suggest roles of SOX9 in colorectal cancer and to delineate the roles of SOX9 in colorectal cancer has been a focus of some recent studies. However, there have been reports of opposing SOX9 functions, promoting and suppressing of proliferation, which suggest diverse, context-specific functions of SOX9 in proliferation. This has been shown in both developmental and cancer contexts. For instance, in normal chondrocytic CFK2 cells and M12 prostate tumor cells, SOX9 overexpression resulted in decreased proliferation rate and cell cycle arrest in G0/G1 (3,4), while Sox9 knockdown in rat mesenchymal stem cells (MSCs) resulted in a marked decrease in proliferation rate through delayed S-phase progression and increased nuclear localization of p21 (5). Furthermore, differential roles of SOX9 have been demonstrated in normal intestinal epithelium; low SOX9 expression was associated with enhanced proliferative capacity and high SOX9 expression suppressed proliferation (6). Another study showed that Sox9 expression facilitated growth and proliferation of colorectal cancer cells, whereas inactivation reduced tumorigenicity (7).

To gain insight into SOX9-mediated transcriptional regulation in colorectal cancer cells, we first attempted to identify its physiological targets on a genome-scale using chromatin immunoprecipitation (ChIP) followed by sequencing (ChIP-seq) in human colorectal cancer cells. Our ChIP-seq analysis revealed a large number of SOX9 transcriptional targets in diverse pathways. Interestingly, motif analysis revealed CCAAT, a binding sequence for the heterotrimeric NF-Y transcription factor, as a preferred
SOX9 binding sequence, in addition to the previously identified classical consensus motif, $\text{A}^A/\text{TA}^A/\text{T}^3\text{AA}^A/\text{G}^G$. Statistical analysis of the ChIP-seq data further revealed that many physiological SOX9 targets through the CCAAT motif are on cell cycle regulatory genes, including the promoters of well-characterized G2/M-specific genes, such as cyclin B1 (CCNB1) (8), cyclin B2 (CCNB2) (9), cyclin dependent kinase 1 (CDK1) (10) and topoisomerase II $\alpha$ (TOP2A) (11). The current study revealed that, in colorectal cancer cells, SOX9 is recruited by NF-Y to the target genes and interacts with NF-Y on CCAAT promoter sequences and that SOX9 is necessary for the function of NF-Y in activating expression of some cell-cycle regulatory gene expressions.

MATERIALS AND METHODS

Cell culture

HT29 and HCT116 cells, both human colon adenocarcinoma cell lines, were purchased from ATCC and cultured in McCoy's 5A Medium (ATCC, Manassas, VA, USA) with 10% FCS (Lonza, Verviers, Belgium) at 37°C in a 5% CO2 atmosphere.

ChIP-seq

ChIP assays were performed as previously described (12) using an anti-SOX9 antibody (Millipore, Billerica, MA, USA) and an anti-NF-YA antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). ChIP-seq experiment was performed from one biological replicate. SOX9 ChIP was subjected to sequencing on Illumina HiSeq 2000. Sequencing of input DNA served as control for peak calling and was also used to generate a control visualization track. Sequences (50-nt reads, single end) were aligned to the human genome (hg19) using BWA algorithm. Only uniquely mapping reads were used in the analysis and duplicate reads were removed. Because the number of final alignments obtained was $>2 \times$ more for the Input data than for the ChIP data, the Input file was adjusted to the ChIP alignment number by randomly removing excess alignments (down-sampling). Aligns were extended in *silico* at their 3′-ends to a length of 150 bp, which is the average genomic fragment length in the size-selected library and assigned to 32-nt bins along the genome. The resulting histograms (genomic ‘signal maps’) were stored in BAR files. Peak locations were determined using the MACS algorithm (v1.3.7.1) with a cutoff $P$-value = 1e-7. In an attempt to optimize peak calling and to reduce the calling of false peaks, the mpforder parameter was set to 16 (default 32) and the $P$-value cut-off was set to 1e-7. Signal maps and peak locations were used as input data to Active Motif’s (Carlsbad, CA, USA) proprietary analysis program, which was used to create Excel spreadsheets containing detailed information on sample comparison, peak metrics, peak locations and gene annotations.

Bioinformatics analysis

The top 1200 peak sequences (i.e. those with the highest fragment density, from −25 to +25 bp relative to the fragment density peak) were analyzed by MEME (13,14), varying the max width and palindrome requirement settings. Identified motifs were further analyzed with TOMTOM (15) and the presence of SOX9-consensus-like motifs in the 17 847 MACS peak sequences was examined using FIMO (16). Both TOMTOM and FIMO were run with default settings. Human Three publicly accessible NF-YA ChIP-seq data were obtained for bioinformatics analysis. The Encyclopedia of DNA Elements (ENCODE) project was used for genome wide comparison analysis and three data sets from UCSC website (HeLa-S3, Accession number: wgEncodeEH002066; GM12878, Accession number: wgEncodeEH002064; K562, Accession number: wgEncodeEH002021) were used to confirm the alignments of the peaks on key genes. Peak locations were intersected with gene features obtained from the RefSeq database using BEDTools (17) and overlap counts were determined using standard UNIX commands. Tag counts in regions containing either a SOX9 peak or a SOX9 peak overlapping with an NF-YA peak were extracted from the signal maps using the Active Motif pipeline mentioned above and plotted in R (18). Pathway analysis was carried out through the use of QIAGEN’s Ingenuity® Pathway Analysis (IPA®, QIA-GEN Redwood City).

ChIP-qPCR

ChIP was performed using the ChIP-IT Express Kit (Active Motif) according to the manufacturer’s instructions, with minor modifications. Cells were cross-linked with 1% formaldehyde, disrupted with a Dounce homogenizer and the chromatin was isolated. The lysates were sonicated to shear the DNA to an average length of 300–600 bp. Chromatin was immunoprecipitated using an anti-SOX9 (Millipore) antibody or anti-NF-YA antibody (Santa Cruz Biotechnology). ChIP DNAs were purified and ChIP enrichment was quantified by quantitative PCR (qPCR). Fold enrichment was determined by the percent input method. Several key SOX9 and NF-YA peaks identified with ChIP-seq assay were validated on multiple biological samples by qPCR, minimum biological triplicates. Standard deviation (SD) was determined using triplicate measurements. PCR primers were designed to amplify regions spanning the center of peaks obtained from ChIP-seq data and a control primer pair was designed to amplify a region in a gene desert on chromosome 12. Primers used for ChIP-qPCR are listed in Supplementary Table S1.

RNA extraction and RT-PCR analysis

Total RNA was extracted using Trizol reagent (Life Technologies, Gaithersburg, MD, USA) and treated with RNase-free DNase (Roche, Indianapolis, IN, USA) according to manufacturer’s instructions. One microgram of total RNA was converted to cDNA using the Transcriptor First Strand cDNA Synthesis Kit (Roche). Real time qRT-PCR analyses were performed using FastStar Universal SYBR Green Master Mix (Roche) and amplified on the Applied Biosystems 7900HT instrument. Primers used were: CCNB1 (forward, 5′-TACCTATGCTGGCTACCACTGT-3′ and reverse, 5′-TACCTATGCTGGCTACCACTGT-3′ and reverse, 5′-TACCTATGCTGGCTACCACTGT -3′).
Relative levels of gene expression were analyzed using the $2^{\Delta \Delta Ct}$ method.

Plasmids and transfection

FLAG-tagged wild-type and HMG-deleted SOX9 constructs were generously provided by Dr Benoit de Crombrugghe (the University of Texas, M. D. Anderson Cancer Center). The FLAG-tagged SOX9−303ΔC construct was derived from the FLAG-tagged wild-type SOX9 construct using primers spanning the sequence encoding the first 303 amino acids of human SOX9. FLAG-SOX9ΔHMG-NLS construct was generated by adding an extra nuclear localization sequence, PKKKRKV, encoded by the sequence CCAAGAAGAAGCGGAAGGTG, to the C terminus of FLAG-SOX9ΔHMG. The fragment of 0.8 kb human TOP2A promoter was cloned into a pGL3 luciferase vector (Promega, Madison, WI, USA). Mutant human TOP2A promoter was cloned into a GL3 luciferase vector of FLAG-SOX9 CCAGAAGAAGCGGAAGGTG, to the C terminus of FLAG-SOX9ΔHMG-NLS. The fragment of 0.8 kb human TOP2A promoter was cloned into a pGL3 luciferase vector (Promega, Madison, WI, USA). Mutant human TOP2A promoter was cloned into a GL3 luciferase vector of FLAG-SOX9 CCAGAAGAAGCGGAAGGTG, to the C terminus of FLAG-SOX9ΔHMG-NLS.

Knockdown of SOX9 and NFYA

Short interfering RNA (siRNA)-mediated SOX9 knockdown was performed as previously described using SOX9 siRNA (19). For NFYA knockdown, cells were transfected with 75 nM siRNA targeting NFYA or control siRNA (Thermo Scientific, Waltham, MA, USA) using DharmaFECT 4 siRNA Transfection Reagent (GE Healthcare, Chalfont St Giles, UK). Cells were harvested 48 h post-transfection for further analysis.

Immunofluorescence and proximity ligation assay (PLA)

HCT116 cells were transfected with FLAG-SOX9ΔHMG, FLAG-SOX9ΔHMG-NLS or FLAG-SOX9−303ΔC plasmids. Forty-eight hours later, cells were fixed with 4% paraformaldehyde for 10 min at room temperature and permeabilized with 0.5% Triton X-100 followed by blocking at 37°C for 30 min. Cells were then incubated with primary antibody against FLAG (SCBT), followed by incubation with the Alexa Fluor 555 goat anti-rabbit secondary antibodies (Life Technologies). The cells were mounted in SlowFade® Gold Antifade Reagent with DAPI (Life Technologies) and the red fluorescence was visualized under a fluorescence microscope (Nikon). The interaction between SOX9 and NF-YA was demonstrated by in situ proximity ligation assay (PLA) using a Duolink in situ red starter kit (Sigma-Aldrich, Louis, MO, USA) according to the manufacturer’s instructions. Briefly, HCT116 and HT29 cells were fixed in 4% paraformaldehyde for 10 min at room temperature and permeabilized with 0.5% Triton X-100 followed by blocking at 37°C for 30 min. Cells were then incubated with primary antibodies against SOX9 (1:500), NF-YA (1:500) or control mouse IgG (1:500), followed by washing and incubation with the secondary antibodies conjugated to PLA probes. After ligation and amplification, the red fluorescence indicating the interaction between SOX9 and NF-YA was visualized under a fluorescence microscope (Nikon).

Western blotting and immunoprecipitation

HCT116 cells and HT-29 cells were lysed in modified RIPA buffer (1% Nonidet P-40, 0.1% sodium deoxycholate, 150 mM NaCl and 1 mM ethylenediaminetetraacetic acid (EDTA) in 50 mM Tris–HCl, pH 7.5) supplemented with 1× protease inhibitor mixture (Sigma-Aldrich). Solubilized proteins were separated by electrophoresis through 10% Tris-glycine gels and transferred onto PVDF membranes. Primary antibodies used for western analysis were rabbit polyclonal anti-SOX9 (Millipore), mouse monoclonal anti-NF-YA (Santa Cruz Biotechnology) and mouse monoclonal anti-β-actin (Santa Cruz Biotechnology). Secondary antibodies used were horseradish peroxidase-conjugated goat anti-mouse and goat anti-rabbit (Santa Cruz Biotechnology). For co-immunoprecipitation, cells were lysed in RIPA buffer and immunoprecipitated overnight at 4°C with 2 μg antibody and 20 μl protein-A/G agarose beads (Santa Cruz Biotechnology). Bead-bound complexes were washed, eluted and visualized by western blotting.

Pull-down assays

Nuclear extracts were obtained from HCT116 cells. A total of 100 μg of nuclear proteins were mixed with 2 μg of biotin-labeled double-stranded TOP2A oligos (wild-type TOP2A oligo: 5’ biotin-TCCCGCTCTCTCAACC TGATTGTTTTATCTCAAACAACC; mutated TOP2A oligo: 5’ biotin-TCCCGCTCTCTCAACCGTTTTGCTTTGTT TTATTCAAACAACC) and 5 μg of polyIC in 1× binding buffer (5× binding buffer: 75 mM Hepes PH7.9, 400 mM NaCl, 75 mM KCl, 0.1 mM EDTA, 5 mM diethiothreitol (DTT), 5 mM phenylmethylsulfonylfluoride (PMSF), and 15% glycerol) for 60 min on ice. Then 40 μl of magnetic beads (Dynabead M-280 streptavidin) were added into the complexes of reactions followed by rotation at 4°C for 30 min. Beads were washed three times with 500 μl of 1× binding buffer. The associated proteins to the biotin-labeled oligos were detected by western blot using either an anti-NF-YA or an anti-SOX9 antibody.

Electrophoretic mobility shift assay (EMSA)

Electrophoretic mobility shift assay (EMSA) was performed with double-stranded, biotin-labeled oligonucleotides using the Gelshift Chemiluminescent EMSA Kit (Active Motif) according to the manufacturer’s instruction. Recombinant human SOX9 protein (OriGene) and/or unlabeled oligonucleotides (cold probes) were added to the biotin-labeled oligonucleotides. The binding reactions were resolved on a non-denaturing polyacrylamide gel and transferred to a nylon membrane, followed by crosslinking using UV cross-linker (Stratagene). The membrane was incubated with HRP conjugated streptavidin. The protein–DNA bindings were detected using SuperSignal West Femto Chemiluminescent Substrate (Thermo Scientific).
**RESULTS**

Identification of SOX9 interaction sites in the genome of human colorectal cancer cells

Aberrant expression of SOX9 in various cancers suggests a role of SOX9 in these diseases. The current study aimed to give insight into roles of SOX9 as a transcription factor by identifying SOX9 target genes in the genome of human colorectal cancer cells. We first carried out ChIP-seq analysis using an antibody specific to SOX9 in HT-29 cells, which express endogenous SOX9 at a considerably high level. MACS peak finding (20) using the default cut-off of \( P \)-value = 1e-7 identified 17 847 peaks of SOX9 binding enrichment. The empirical false discovery rate, calculated by MACS with a ChIP input sample swap, was 0.01%. For each peak, the distance to RefSeq transcription start(s) (TSSs) was determined. Figure 1A (left) shows that SOX9 binding sites have a strong preference for TSSs (distance = 0). Figure 1A (right) demonstrates, at higher resolution, that the majority of SOX9 binding sites are located just upstream of the TSS. We also annotated the MACS SOX9 peak locations to RefSeq gene features. As a control, an equal number (17 847) of random genomic locations (generated by sampling to RefSeq gene features). As a control, an equal number (17 847) of random genomic locations (generated by sampling to RefSeq gene features) were annotated in the same way (Figure S1). The data shown in Figure 1A and B thus suggest that in colorectal cancer cells, SOX9 is likely to bind mainly to the proximal promoters of target genes and to some extent through 5′ UTR regions. This is consistent with previous reports by others, including SOX9 ChIP-on-chip analysis of chondrocytes (21) and embryonic gonads (22) and SOX9 ChIP-seq analysis of hair follicle stem cells (23). Several previous studies have identified the sequence \( \AA/\AA/\AA/\AA/\AA \) as the canonical consensus motif for SOX9 (21,24). To confirm whether SOX9 also binds to DNA through this motif in colorectal cancer cells, we used the motif discovery tool MEME. The top 1200 peak sequences (50 bp; ±25 bp relative to summits) were submitted to MEME using different parameters. The three main motifs identified are shown in Figure 1C and are referred to as Motif 1, 2 and 3 throughout this study. Motif 2 is a perfect match to the classical SOX9 consensus sequence. Motif 3 is an inverted repeat of the 7-bp core consensus sequence separated by 4 bp. This dimeric binding site has been reported to be required for SOX9 dimerization to regulate gene expression in chondrogenesis (25). To our surprise, Motif 1, which has not previously been reported as a SOX9 binding motif, was the most significant motif in all runs (unless searching for palindromes only), with even relatively higher affinity for SOX9, as shown by the number of tags compared to Motif 2 and/or 3 (Figure 1D).

**SOX9 binding sites overlap NF-YA sites in genome of human colorectal cancer cells**

TOMTOM analysis (15) further demonstrated that Motif 1 sequence contained the core DNA-binding element CCAAT, flanked by 5′ AG and 3′ CA/GG nucleotides sequence, which are identical to the preferred NF-YA binding motif obtained from the JASPAR CORE database (E-value of 1.7e-11) (Figure 2A). The NF-YA ChIP-seq data from ENCODE (Accession number: ENCSR000EGR; k562, human leukemia cells) contained 7647 peaks, of which 2564 overlapped with our SOX9 ChIP-seq peaks. NF-YA is a subunit of the heterotrimeric NF-Y transcription factor and therefore NF-YA ChIP-seq peaks represent binding sites for NF-Y. This was confirmed by NF-YB ChIP-seq, peaks of which were identical to those of NF-YA (26). To visualize the correlation between the SOX9 and NF-Y ChIP-seq data, we determined the number of tags in the NF-YA ChIP for the genomic regions corresponding to all of the 17 847 SOX9 peaks, regardless of whether they overlapped with a called NF-Y peak or not. Note that genomic locations that had only a NF-YA peak but no SOX9 peak were excluded from the analysis. SOX9 peaks were further annotated with MEME Motif 1 and Motif 2 and/or 3 using the FIMO software (16). The scatter plot in Figure 2B represents the SOX9 peak tag counts versus the NF-YA data tag counts for the 17 847 SOX9 peaks, which are color-coded depending on the presence or absence of Motifs 1 (NF-Y consensus) and Motifs 2/3 (SOX9 consensus). Whereas the data points broadly scatter, the plot clearly demonstrates that the SOX9 peaks with Motif 1 also have higher NF-YA peak metrics (green and red), whereas SOX9 peaks without Motif 1 (blue and black) have low NF-YA peak metrics. Linear regression lines confirm the higher correlation between SOX9 and NF-YA peak metrics with Motif 1. Among the
SOX9 peaks without Motif 1 (blue and black), the presence of the SOX9-consensus (Motif 2/3; blue) has only a minimal effect on the number of SOX9 tags, whereas overlapping SOX9 and NF-Y peaks with Motif 1 were greatly enriched in the promoter region (75% within 3000 bp of TSS), leaving only 25% located outside promoter regions, including in distal enhancers. Taken together, the results of our statistical analysis of promoter sites enriched for SOX9 and NF-YA strongly suggest that both proteins likely bind to the same genomic sites.

We then investigated individual NF-Y target genes in the light of suggested cooperation between SOX9 and NF-YA. TOP2A, CCNB1, CCNB2 and CDK1 are all well characterized NF-Y transcriptional targets through CCAAT motifs. Alignment of SOX9 and NF-YA ChIP-seq peaks revealed that the peaks overlapped precisely in the proximal promoters of TOP2A, CCNB1 (Figure 2C, left), CCNB2 and CDK1 (Supplementary Figure S2). Most other motif 1 genes also showed overlapping SOX9 and NF-YA peak sequences (data not shown). Note that Motif 2 genes (represented by USP15 and MTCH1) or Motif 3 genes (represented by SASH1 and CDCA7L) had SOX9 peaks, but not NF-YA peaks (Figure 2C).

To confirm that NF-YA binding sites are conserved among different cell types, we aligned NF-YA binding peaks on the representative genes, including CCNB1, CDK1 and TOP2A, using three publicly accessible NF-YA ChIP-seq data from UCSC website (HeLa-S3, Accession number: wgEncodeEH002066; GM12878, Accession number: wgEncodeEH002064; K562, Accession number: wgEncodeEH002021). A total of 72 out of randomly selected 100 SOX9 peaks in the proximal promoters had precisely overlapping peaks in all three NF-YA ChIP-seq, indicating conserved binding sites of NF-YA on those target genes. Three representative peak alignments are shown in Supplementary Figure S3. We verified randomly selected 15 peaks by NF-YA ChIP-qPCR in HT-29 cells (Supplementary Figure...
Figure 2. SOX9 and NF-Y co-occupy many target genes. (A) SOX9 and NF-YA share high homology of Motif 1 sequences identified by TOMTOM analysis. (B) Scatter plot of SOX9 and NF-YA peaks containing different combinations of Motif 1 and/or Motif 2–3. Different colors of dots represent genes with following Motifs: Motif 1 only (green), Motif 1 with Motif 2 and/or Motif 3 (red), no Motifs 1, 2 or 3 (blue) and no Motif 1 but Motif 2 and/or Motif 3 (black). X- and y-axes represent number of tags for NF-YA and SOX9 peaks, respectively. (C) Representative readouts of peaks from SOX9 ChIP-seq (red), NF-YA ChIP-seq (blue) and an input control (black) for indicated genes. Peaks from SOX9 and NF-YA ChIP-seq analyses overlap only on Motif 1 genes.

S4). The results suggested that the rest of NF-YA peaks obtained from other cells can also be expected in HT29 cells. The peaks obtained by ChIP-seq and used for the motif alignment were confirmed by ChIP-qPCR with anti-SOX9 and anti-NF-YA antibodies in separate ChIP analysis of HT29 cells (Supplementary Figure S5A and S5B) and HCT116 cells (data not shown), which validated the ChIP-Seq data for regions highly enriched for SOX9 and NF-YA binding and confirmed that the findings were consistent in two colorectal cancer cell lines. These experiments confirmed that sites highly enriched in SOX9 binding overlap the NF-YA binding sites around the TSSs (within 500 bp of TSSs) of TOP2A, CCNB1, CCNB2 and CDK1 in colorectal cancer cells. In order to further confirm that SOX9 peaks are specific to some target sites and not to all of NF-YA binding sites, we verified by SOX9 ChIP-qPCR as well as NF-YA ChIP-qPCR in both HT-29 cells and HCT116 that only NF-YA has high binding affinity to some of its target genes, such as the promoter region of LRIF1, but not SOX9 (Supplementary Figure S6A and S6B). This is addi-
SOX9 and NF-Y bind to the target genes on CCAAT and form a complex in the nuclei of colorectal cancer cells

The overlapping SOX9 and NF-Y binding sites suggested a possible direct association between SOX9 and NF-Y in the chromatin. To test whether SOX9 and NF-Y interact in the nuclei of colorectal cancer cells, we performed in situ PLA on HT29 and HCT116 cells. In situ PLA results in high concentration of fluorescence only if two proteins are in close proximity (<40 nm) that indicates protein to protein interaction. In situ PLA using anti-SOX9 and anti-NF-Y antibodies showed positive signals in the nuclei of HCT116 (Figure 4A) and HT29 (Supplementary Figure S7) cells, indicating that SOX9 and NF-Y likely form a protein complex.

To determine whether CCAAT is necessary for SOX9 and NF-YA binding to the target genes, we performed biotin-mediated pull down assay using human wild-type TOP2A oligo (TOP2A WT) and the mutated TOP2A oligo (TOP2A M). There are four ATGGG sequences on the human TOP2A promoter (−221 to +37 bp), one of which is located in the center of SOX9 peak obtained from our ChIP-seq analysis (−106 to −102 bp) (Figure 4B). For the mutated TOP2A oligo, a mutation by 1 bp was made in the CCAAT to CAAAA in this location. Both SOX9 and NF-YA bind to wild-type Topo2A promoter, and the mutation in CCAAT resulted in a significant reduction of both SOX9 and NF-YA binding (in vitro) (Figure 4C). This confirmed that SOX9 and NF-Y both require CCAAT to bind to their target genes. This was further demonstrated by overexpression of wild-type and mutated TOP2A plasmids, followed by ChIP-qPCR, showing that 1-bp mutation of CCAAT reduced both SOX9 and NF-YA binding to TOP2A promoter (Figure 4D). This mutation also reduced the promoter activity of TOP2A ( Supplementary Figure S8). To test whether or not SOX9 directly binds to DNA through CCAAT motif without NF-Y, we performed EMSA assay using recombinant human SOX9 proteins (Figure 4D). While recombinant SOX9 clearly bound to RASSF3 (Motif 3 sequence), it did not bind to TOP2A (Motif 1) promoter sequences (Figure 4E). Prior to this experiment, we confirmed SOX9 binding to both TOP2A and RASSF3 by ChIP-qPCR using HT-29 (Figure 4F). In addition, HMG DNA binding domain did not affect SOX9 binding to the promoters of CCNB1, CDK1 or TOP2A (Supplementary Figure S9C). Taken together, these results strongly suggest that SOX9 requires NF-Y to bind to the target DNA through CCAAT.

To further identify the SOX9 domain responsible for binding to NF-Y, we transfected HCT116 cells with expression constructs encoding FLAG-tagged wild-type SOX9 (FLAG-WT SOX9); C-terminus-deleted SOX9, carrying 303 amino acids from the N-terminus (FLAG-SOX9−303 ΔC); and HMG domain-deleted SOX9 fused with a nuclear localization signal (NLS) at the C-terminus (FLAG-SOX9 ΔHMG-NLS) (Figure 5A). FLAG-SOX9 ΔHMG-NLS was generated to compensate for the lack of an NLS in HMG-deleted SOX9. We first confirmed by western analysis that each FLAG-tagged protein was expressed (Supplementary Figure S9A), and, immunofluorescence analysis with anti-FLAG antibody, that the fused extra NLS enabled SOX9 to translocate into the nucleus (Supplementary Figure S9B) in HCT 116 cells. In situ PLA using anti-FLAG and anti-NF-YA antibodies was then performed on HCT116 cells transfected with constructs encoding the three SOX9 variants. As shown in Figure 5, neither HMG domain-deleted SOX9 nor C-terminus deleted SOX9 formed protein complex with NF-Y, whereas Flag-SOX9 ΔHMG-NLS did. Taken together, our data show that the C-terminus of SOX9 is required for interaction with NF-Y in the nucleus (Figure 5B).

NF-Y recruits SOX9 to CCAAT promoters whereas SOX9 is necessary for transactivation of target genes by NF-Y

NF-Y binding to the CCAAT motifs plays a role in the opening of target promoter chromatin and facilitates the recruitment of many cofactors to modulate transcriptional activity (27,28). To determine whether NF-Y also mediates SOX9 recruitment to the CCAAT boxes of target promoters, we carried out siRNA-mediated knockdown of NF-YA in HCT116 cells followed by SOX9 ChIP analysis (Figure 6A). NF-YA knockdown led to a significant decrease in SOX9 affinity to the promoters of CCNB1 and CDK1 (Figure 6B). This observation suggested that NF-Y recruits SOX9 to the target promoters. As expected, upon NF-YA inactivation, expression of both CCNB1 and CDK1 was significantly downregulated (Figure 6D). Next, to further investigate the functional aspect of SOX9 occupancy on these genes, we knocked down SOX9 in HCT116 cells and measured NF-YA occupancy, as well as expression levels of the same target genes (Figure 6A). SOX9 knockdown led to enhanced affinity of NF-YA binding to the CCNB1 and CDK1 promoters (Figure 6C). Although one might expect upregulated expression of NF-Y targets with enhanced NF-YA binding, expression of both CCNB1 and CDK1 was significantly downregulated in SOX9 knockdown cells (Figure 6D). Taken together, these data support the conclusion that SOX9 is recruited by NF-Y to the promoters of some key
cell cycle regulatory genes, and that SOX9 is required for the NF-Y transactivation of these genes.

**DISCUSSION**

SOX9 has been shown to be critical for cell differentiation in diverse tissues. Recent ChIP-seq analyses as well as ChIP-on-chip studies in SOX9 expressing tissues have revealed many tissue specific SOX9 transcriptional targets. However, there has not been a report of genome-wide ChIP analysis in intestinal or colorectal cancer cells. Applying the motif discovery tool MEME to SOX9 ChIP-targets in intestinal epithelium or colorectal cancer cells. 

[Figure 3. Pathway analysis of ChIP-Seq-identified SOX9 target genes. SOX9 target genes identified based on ChIP-seq were classified into two groups based on motif and pathway analysis was performed using IPA software. The top 20 pathways ($P < 0.05$) ranked by number of genes are presented. Black bars represent pathways unique to each group.](https://academic.oup.com/nar/article-abstract/43/13/6257/2414229)

There have been four SOX9 ChIP data reported (21–23,34), but none of them indicated SOX9 association with NF-Y on CCAAT and that SOX9 does not directly bind to CCAAT.

New finding of SOX9 affinity to CCAAT could also be associated with the previously reported differential roles of SOX9 expressed at high and low levels (6). At a high expression level, SOX9 may bind through all three motifs, Motif1, Motif2 + Motif3. Further, our mutagenesis analyses as well as in vitro binding assays confirmed CCAAT as the interaction sequences of SOX9 and NF-Y complexes. Our data showed that SOX9 does not require its DNA binding domain and that SOX9 binding on the target genes are NF-Y dependent. This indicates that SOX9 binding is through NF-Ys on CCAAT and that SOX9 does not directly bind to CCAAT.

**Table: Pathway analysis of ChIP-Seq-identified SOX9 target genes.** SOX9 target genes identified based on ChIP-seq were classified into two groups based on motif and pathway analysis was performed using IPA software. The top 20 pathways ($P < 0.05$) ranked by number of genes are presented. Black bars represent pathways unique to each group.
**Figure 4.** SOX9 and NF-YA likely form a protein complex. (A) SOX9/NF-YA interaction demonstrated by in situ PLA in HCT116 cells. Red signal indicates interaction of SOX9 and NF-YA. Nuclei were counterstained with DAPI. (B) The sequence of partial TOP2A promoter (−221 to +37 bp) containing the center of SOX9 and NF-YA peaks. The center of the peak sequences of SOX9 and NF-YA enriched region, ATTGG (−106 to −102 bp), is marked by a box. Biotin labeled wild-type TOP2A oligo (WT TOP2A) and the mutated TOP2A (M TOP2A) by 1 bp were synthesized as following sequences, respectively. WT TOP2A: TCCCGCCTCCCTAACCTGATTGGTTTATTCAAACAAACC. M TOP2A: TCCCGCCTCCCTAACCTGTTTGGTTTATTCAAACAAACC. (C) The biotin-mediated pull down assay showed that SOX9 and NF-YA in HCT116 nuclear extracts bind to biotin labeled wild-type TOP2A oligo, but 1-bp mutation of CCAAT resulted in a significant reduction of both SOX9 and NF-YA binding. (D) pGL3-WT TOP2A and pGL3-M TOP2A plasmids were transfected into HCT116 cells, followed by ChIP-qPCR using anti-SOX9 and anti-NF-YA antibodies 48 h post-transfection. A total of 1-bp mutation of CCAAT reduced the SOX9 and NF-YA binding to TOP2A promoter. (E) EMSA (Figure 4E, left) was performed with biotin-labeled oligonucleotides for TOP2A (TOP2A bio-F: 5′-biotin-TCCCGCCTCCCTAACCTGATTGGTTTATTCAAACAAACC) and RASSF3 (RASSF3 bio-F: 5′-biotin-ATGACAAGGTCTTTTTGAAGTCACCTGGAATGCTCCCTTT). Both sequences contain the SOX9 peak center obtained from our ChIP-seq. Recombinant human SOX9 protein directly binds to RASSF3, but not TOP2A. western blot (Figure 4E, right) was performed on the same membrane used for EMSA to detect recombinant human SOX9 protein. (F) SOX9 and NF-YA ChIP-qPCR analysis showed that SOX9 binds to both TOP2A and RASSF3 (Motif 3), while NF-YA binds only to TOP2A, but not to RASSF3.
Figure 5. SOX9 C terminus is responsible for the interaction with NF-YA. (A) Schematic representation of structures of human wild-type and mutant SOX9 expressed from indicated constructs. DIM: dimerization domain; HMG domain: the DNA-binding domain; K2 and TA: transactivation domains; PQA: proline-, glutamine- and alanine-rich domain; NLS: nuclear localization sequence. (B) In situ PLA using anti-FLAG and anti-NF-YA antibodies in HCT116 cells transfected with FLAG-tagged mutant SOX9 constructs depicted in (A). Nuclei were counterstained with DAPI.

Our *in situ* PLA results indicated that SOX9 and NF-Y comprise a protein complex in the nucleus. ChIP analysis of NF-Y knockdown cells strongly suggest that NF-Y is necessary for SOX9 binding to the CCAAT sites. This observation is consistent with the roles of NF-Y, in that histone-fold domain protein NF-Y pre-sets the promoter architecture that allows other regulatory proteins access (11). On the other hand, SOX9 knockdown cells showed decreased expression of NF-Y target genes, indicating that SOX9 is critical for NF-Y mediated transactivation of these genes. Taken together, the data show that SOX9 binds to some cell cycle regulatory genes as a cofactor of NF-Y through the CCAAT motif and facilitates NF-Y mediated transactiva-
Figure 6. Both SOX9 and NF-Y are required for transcriptional regulation of target genes. (A) siRNA-mediated NF-YA and SOX9 knockdown in HCT116 cells were confirmed by western analysis. (B) SOX9 ChIP-qPCR analysis showed that both NF-YA knockdown cells and SOX9 knockdown cells resulted in decreased binding affinity of SOX9 to \textit{CCNB1} and \textit{CDK1} promoters compared to the cells treated with control siRNA (Ctrl). (C) NF-YA ChIP-qPCR analysis showed that decreased NF-YA expression resulted in reduction of NF-YA binding affinity to \textit{CCNB1} and \textit{CDK1}, however, SOX9 knockdown enhanced NF-YA binding affinity to these genes. (D) In NF-YA knockdown cells, expression of the corresponding mRNAs was downregulated. Upon SOX9 knockdown, although NF-YA binding affinity was enhanced, expression of the corresponding mRNAs was downregulated. *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$. 

---

**NF-YA**

- Ctrl: Black
- NF-YA KD: Gray
- SOX9 KD: White

**SOX9**

- Ctrl: Black
- NF-YA KD: Gray
- SOX9 KD: White

**β-actin**

- Ctrl: Black
- SOX9 KD: Gray

---

**CCNB1 and CDK1**

**% of input**

- Ctrl: Black
- NF-YA KD: Gray
- SOX9 KD: White

---

**Relative mRNA levels**

- Ctrl: Black
- NF-YA KD: Gray
- SOX9 KD: White

---

**Legend**

- **Ctrl**: Control
- **NF-YA KD**: NF-YA Knockdown
- **SOX9 KD**: SOX9 Knockdown
In SOX9 depleted cells, although NF-Y target cell cycle genes exhibited downregulation, the cells did not show significant cell cycle arrest. This is perhaps due to the presence of many other SOX9 target genes that regulate proliferation rate directly or indirectly, the expression of which is also altered upon SOX9 inactivation. For example, insulin-like growth factor (IGF)-binding protein 4 (IGFBP-4), an inhibitor of the IGF/IGF receptor pathway, is a direct transcriptional target of SOX9, whose expression is significantly downregulated upon inactivation of SOX9 (19).

SOX9 binds to an inverted repeat of a heptameric sequence, and this dimeric binding is necessary for SOX9-dependent transactivation of downstream genes, at least in some tissues including cartilages (44). For example, SOX9 dimerization mutants have been identified in some camptomelic dysplasia patients, suggesting the importance of the repetition of the sequence (24). Our ChIP-seq data suggested that some of the genes with high affinity for SOX9 contained inverted repeats of putative sequences (Motif 3); however, such repeats were also observed in many of the peak sequences of Motif 2 genes, allowing spacers of 2–14 bp. We hypothesize that dimerization of SOX9 is likely also required for transactivation of some genes in colorectal cancer cells. However, functional assays of each gene are needed to confirm the mechanism in detail.

SOX9 has also been shown to be indispensable for stem cell maintenance in some tissues, such as hair follicle, biliary and pancreatic ductal epithelium and mammary epithelium (23, 29, 44). Our ChIP-seq analysis showed enriched SOX9 binding to some intestinal stem cell (ISC) marker genes such as BMI1, Lrig1 and Lgr5, also suggesting a potential role of SOX9 for ISC regulation. SOX9 consensus sequences are identifiable within the peak sequences of each of these genes. A recent study demonstrated the significance of cell type specific NF-Y regulation of master ESC transcription factor expression through distal enhancer binding (26, 30). Our ChIP-seq data showed enrichment of SOX9 binding to promoters of some of the major ISC markers, including BMI1, Lrig1 and Lgr5. Neither CCAAT boxes nor peaks overlapping with NF-Y ChIP-seq peaks were identified, but SOX9 consensus sequences were observed within those peaks. We speculate that SOX9 may also be involved in stem cell maintenance in the intestinal epithelium. However, SOX9 is not likely to be involved in the NF-Y-mediated stem cell regulation complexes in the distal enhancer (26).

Although, SOX9 has been reported to inhibit or sustain cell proliferation in different cell types, on the other hand, SOX9 is expressed in most human colorectal cancers as well as in human colorectal cancer cell lines. Our finding of activation of proliferative genes through NF-Y, therefore, gives an insight into the oncogenic aspect of SOX9 and helps to explain why anti-oncogenic protein, SOX9 is highly expressed in some cancers including most colorectal cancer cells.

ACKNOWLEDGEMENT
We would like to thank Dr Daniel Lacorazza and Dr Chen Shik Park for helpful discussions.

FUNDING
Department of Pathology, Texas Children’s Hospital (in part); Department of Pathology & Immunology, Baylor College of Medicine; Public Health Service Grant [P30 DK56338]. Funding for open access charge: Department of Pathology & Immunology, Baylor College of Medicine; Departmental funds of Department of Pathology, Texas Children’s Hospital; Department of Pathology & Immunology, Baylor College of Medicine.

Conflict of interest statement. None declared.

REFERENCES

SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.


